Ontology highlight
ABSTRACT:
SUBMITTER: Kruger DT
PROVIDER: S-EPMC7053245 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
Kruger Dinja T DT Jansen Maurice P H M MPHM Konings Inge R H M IRHM Dercksen Wouter M WM Jager Agnes A Oulad Hadj Jamal J Sleijfer Stefan S Martens John W M JWM Boven Epie E
Molecular oncology 20200207 3
We determined whether progression-free survival (PFS) in metastatic breast cancer (MBC) patients receiving everolimus plus exemestane (EVE/EXE) varies depending on circulating tumour DNA (ctDNA) characteristics. Baseline plasma cell-free DNA (cfDNA) from 164 postmenopausal women with ER-positive, HER2-negative MBC refractory to a nonsteroidal aromatase inhibitor and treated with standard EVE/EXE (Everolimus Biomarker Study, Eudract 2013-004120-11) was characterised for 10 relevant breast cancer ...[more]